TY - JOUR
T1 - Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease
AU - Alisi, Anna
AU - Ceccarelli, Sara
AU - Panera, Nadia
AU - Prono, Federica
AU - Petrini, Stefania
AU - De Stefanis, Cristiano
AU - Pezzullo, Marco
AU - Tozzi, Alberto
AU - Villani, Alberto
AU - Bedogni, Giorgio
AU - Nobili, Valerio
PY - 2013/6/26
Y1 - 2013/6/26
N2 - Atypical fibroblast growth factors (FGF) 21 and 19 play a central role in energy metabolism through the mediation of Klotho coreceptor. Contradictory findings are available about the association of FGF21 and FGF19 with nonalcoholic fatty liver disease (NAFLD) in humans. We investigated the association of serum FGF21, FGF19 and liver Klotho coreceptor with non-alcoholic steatohepatitis (NASH) and fibrosis in children with NAFLD. Serum FGF21 and FGF19 were measured in 84 children with biopsy-proven NAFLD and 23 controls (CTRL). The hepatic expression of Klotho coreceptor was measured in 7 CTRL, 9 patients with NASH (NASH+) and 11 patients without NASH (NASH-). FGF21 and FGF19 showed a tendency to decrease from CTRL (median FGF21 = 196 pg/mL; median FGF19 = 201 pg/mL) to NASH- (FGF21 = 89 pg/mL; FGF19 = 81 pg/mL) to NASH+ patients (FGF21 = 54 pg/mL; FGF19 = 41 pg/mL) (p2 = 0.87, p2 = 0.57, p2 = 0.67, p
AB - Atypical fibroblast growth factors (FGF) 21 and 19 play a central role in energy metabolism through the mediation of Klotho coreceptor. Contradictory findings are available about the association of FGF21 and FGF19 with nonalcoholic fatty liver disease (NAFLD) in humans. We investigated the association of serum FGF21, FGF19 and liver Klotho coreceptor with non-alcoholic steatohepatitis (NASH) and fibrosis in children with NAFLD. Serum FGF21 and FGF19 were measured in 84 children with biopsy-proven NAFLD and 23 controls (CTRL). The hepatic expression of Klotho coreceptor was measured in 7 CTRL, 9 patients with NASH (NASH+) and 11 patients without NASH (NASH-). FGF21 and FGF19 showed a tendency to decrease from CTRL (median FGF21 = 196 pg/mL; median FGF19 = 201 pg/mL) to NASH- (FGF21 = 89 pg/mL; FGF19 = 81 pg/mL) to NASH+ patients (FGF21 = 54 pg/mL; FGF19 = 41 pg/mL) (p2 = 0.87, p2 = 0.57, p2 = 0.67, p
UR - http://www.scopus.com/inward/record.url?scp=84879468929&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879468929&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0067160
DO - 10.1371/journal.pone.0067160
M3 - Article
AN - SCOPUS:84879468929
VL - 8
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 6
M1 - e67160
ER -